In the present study, to validate our conjecture, immunohistochemical staining was used to detect the expression levels of integrin β3 and AXL in cancer biopsy samples before erlotinib treatment and after acquired erlotinib resistance in patients with NSCLC. Here, AXL is linked to cancer.